Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.
about
Intravenous immunoglobulins for the treatment of infections in patients with haematological cancersAntibiotics for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationAntibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationEmpirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancerAntibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapyQ24235340Antibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationIntravenous immunoglobulins for the treatment of infections in patients with haematological cancersAntibiotics plus colony stimulating factors versus antibiotics alone for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationProphylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapyAntibiotics plus colony stimulating factors versus CSFs alone and antibiotics plus CSFs versus no prophylaxis for the prevention of infections in cancer patients receiving myelosuppressive chemotherapy or haematopoetic stem cell transplantationProphylactic antibiotics and G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapyAntibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapyAdditional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patientsGuidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveProphylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapyCiprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistanceIfosfamide, epirubicin, and etoposide (IEV) mobilize peripheral blood stem cells more efficiently than cyclophosphamide/etoposide.Management of myelodysplastic syndromes in the geriatric patient.Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia.Filgrastim improves survival in lethally irradiated nonhuman primatesChild with aplastic anemia: Anesthetic management.Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: a retrospective multicenter study.Prevention of bacterial infection in pediatric oncology: what do we know, what can we learn?Risk Adapted Management of Febrile Neutrepenia and Early Cessation of Empirical Antibiotherapy in Hematopoietic Stem Cell Transplantation Setting.Low rates of antibiotic resistance and infectious mortality in a cohort of high-risk hematology patients: A single center, retrospective analysis of blood stream infectionFeasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia.The impact of a change in antibacterial prophylaxis from ceftazidime to levofloxacin in allogeneic hematopoietic cell transplantationImpact of peri-transplant vancomycin and fluoroquinolone administration on rates of bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients: a 12-year single institution study.Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantationPostinduction Supportive Care of Pediatric Acute Myelocytic Leukemia: Should Patients be Kept in the Hospital?Discrete choice experiment to evaluate factors that influence preferences for antibiotic prophylaxis in pediatric oncology.Attitudes toward infection prophylaxis in pediatric oncology: a qualitative approachAntibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.Randomized double blind trial of ciprofloxacin prophylaxis during induction treatment in childhood acute lymphoblastic leukemia in the WK-ALL protocol in Indonesia.A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findingsFebrile neutropenia in hematologic malignancies.Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update.Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors.Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.
P2860
Q24186274-12C2C663-EFE5-4485-9FEA-E37718D43BC1Q24186282-58D59BC0-9E79-4274-BD34-DBA857249F9BQ24200225-3932F9F9-E4F8-4F67-A148-F2293B2138E5Q24201136-711DA220-095D-499A-A091-34FFC1C2D647Q24203869-38E394EF-7CD8-40BE-8016-087EB3EAA782Q24235340-D4438141-2961-444C-AA73-EFCAE45C2F29Q24235345-0B78B1A3-9FE9-4125-BE81-5A5D69AF80D4Q24236448-7A07D183-D55E-4A2A-A0FB-D131467AB79FQ24241475-E0521487-3CC2-48F4-88A8-4017E97F60F0Q24241680-90A38CF0-F14D-4606-AF38-6B074A74882DQ24241689-BE52BD49-596E-4BF6-8DC2-FB82C38D9111Q24243543-7845ED94-BFD4-4CCD-944E-CB0E979B1AECQ24245774-461F621B-3B10-4FDC-8240-C5EBDE650957Q24246468-C0597B44-D9AC-44F4-8563-C68F163580C4Q28388806-CAF6935F-50D8-411A-BEDE-4ED652A50A3EQ28571264-A85048AB-DE36-4D7D-91AA-0261229C5C2EQ31125417-55E81183-D39A-471B-9B3F-3B2408127622Q33375131-D067EF50-B84A-4027-8980-6570B245DEA5Q33389333-925E7380-D0DB-434F-9871-84405A9839DFQ33390157-A29ADA43-3898-4C45-8A03-BD911A58F6F5Q33390547-CF6AAC17-D28F-48DE-9BC3-0157E54CDF5EQ33404444-9E4D8796-CCF9-418D-AC8C-1D7286515D60Q33405470-895F88A8-3B4C-40D5-B1EA-4D063D6A3935Q33559453-68DC7C71-DD33-4171-AB42-E6272DB746A5Q33572014-8373BE1E-AFCF-427F-99E3-00F97050811EQ33708035-90A51788-67BF-4861-B960-F40AA510111EQ33779342-0AA27C14-160E-4888-B8DC-F3B91FEC4069Q34027816-7B1BE93E-AA08-4147-8970-57F994A2BFE4Q34175284-96B62345-691C-406F-BECA-67822FCA4E8CQ34311369-8C1563D9-4B8F-4FD6-A379-E0BD71A6BBC2Q34346926-E211797D-4EDA-429F-A6EE-B7A680CBF988Q34452116-804C1BFE-2F6F-472F-887A-899FF2D84B5AQ34462307-653D5DD2-522F-41FE-959D-7A1A2F5A5E9DQ34570947-D72B2A9C-A042-4404-894B-600C0FB3C382Q34583481-66DDAB53-AC2B-4B20-B4E3-9FE0EF41EAA9Q34627796-4CA457AE-ED5B-4B50-A1A1-22F68CBEDEEEQ34655730-37A5048A-A774-4D3C-AC5C-B3EF05175602Q34667166-BD1EB58E-889E-4672-B96A-76B3EA4A1B11Q34670717-5BCE12DC-18D2-4D14-A084-2C632A35DA5DQ34678894-795730FD-936F-4D8A-AA5C-632F8EC85CA3
P2860
Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.
@ast
Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.
@en
type
label
Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.
@ast
Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.
@en
prefLabel
Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.
@ast
Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.
@en
P1476
Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.
@en
P2093
Abigail Fraser
Anat Gafter-Gvili
P304
P356
10.7326/0003-4819-142-12_PART_1-200506210-00008
P407
P433
P577
2005-06-01T00:00:00Z